View ValuationHLscience 将来の成長Future 基準チェック /06現在、 HLscienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長30.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.お知らせ • Mar 07HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea分析記事 • Nov 05HLscience Co., Ltd. (KOSDAQ:239610) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe HLscience Co., Ltd. ( KOSDAQ:239610 ) share price has fared very poorly over the last month, falling by a...分析記事 • Nov 05More Unpleasant Surprises Could Be In Store For HLscience Co., Ltd.'s (KOSDAQ:239610) Shares After Tumbling 25%HLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders that were waiting for something to happen have been dealt a blow...Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.お知らせ • Mar 08HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$44.7m).分析記事 • Nov 13HLscience Co., Ltd.'s (KOSDAQ:239610) 30% Share Price Plunge Could Signal Some RiskHLscience Co., Ltd. ( KOSDAQ:239610 ) shares have retraced a considerable 30% in the last month, reversing a fair...分析記事 • Sep 24There's Reason For Concern Over HLscience Co., Ltd.'s (KOSDAQ:239610) Massive 26% Price JumpHLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders would be excited to see that the share price has had a great month...New Risk • Sep 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 110% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩87.4b market cap, or US$65.8m).Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 50% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩103.1b market cap, or US$79.2m).Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,400, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total loss to shareholders of 51% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Sep 30HLscience Co., Ltd. (KOSDAQ:A239610) announces an Equity Buyback for KRW 3,000 million worth of its shares.HLscience Co., Ltd. (KOSDAQ:A239610) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares according to the contract with Mirae Asset Daewoo Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on October 04, 2023. As of September 29, 2022, the company had 145,575 and 0 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 17x in the Personal Products industry in South Korea. Total loss to shareholders of 65% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Is New 90 Day High Low • Feb 26New 90-day low: ₩40,900The company is down 3.0% from its price of ₩42,238 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period.お知らせ • Feb 06HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Dec 28New 90-day high: ₩47,700The company is up 1.0% from its price of ₩47,050 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.Upcoming Dividend • Dec 22First Dividend Is ₩400 Per ShareWill be paid on the 21st of April to those who are registered shareholders by the 29th of December. This is the first dividend for HLscience since going public. The average dividend yield among industry peers is 0.6%.Is New 90 Day High Low • Oct 16New 90-day low: ₩44,000The company is down 22% from its price of ₩56,300 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩44,550The company is down 18% from its price of ₩54,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、HLscience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A239610 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202516,706-11,917-7,570-7,047N/A9/30/202518,099-11,320-5,682-5,050N/A6/30/202518,142-10,108-5,009-4,101N/A3/31/202517,611-8,719-5,600-4,327N/A12/31/202417,664-7,877-4,833-3,590N/A9/30/202419,695-4,127-6,758-5,321N/A6/30/202422,053-3,475-5,688-4,419N/A3/31/202423,837-2,239-4,404-3,026N/A12/31/202325,587-1,376-4,429-1,955N/A9/30/202327,857-1,696-4,679-2,020N/A6/30/202334,979-1,200-6,897-1,445N/A3/31/202344,887-761-5,4354,867N/A12/31/202252,7581,592-8,0293,955N/A9/30/202264,6015,081-15,2874,810N/A6/30/202275,0337,598-15,0936,716N/A3/31/202290,45012,348-14,4914,883N/A12/31/2021104,37513,539-8,27510,559N/A9/30/2021115,88815,3433,18313,591N/A12/31/2020143,03619,64213,56414,970N/A12/31/201523,7053,533N/A3,105N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A239610の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A239610の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A239610の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A239610の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A239610の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A239610の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/12 13:01終値2026/05/12 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLscience Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Kyung-rae HanDaishin Securities Co. Ltd.null nullDBS Bank LtdSo Min OhEugene Investment & Securities Co Ltd.3 その他のアナリストを表示
Reported Earnings • Mar 20Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024)Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 07HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea
分析記事 • Nov 05HLscience Co., Ltd. (KOSDAQ:239610) May Have Run Too Fast Too Soon With Recent 25% Price PlummetThe HLscience Co., Ltd. ( KOSDAQ:239610 ) share price has fared very poorly over the last month, falling by a...
分析記事 • Nov 05More Unpleasant Surprises Could Be In Store For HLscience Co., Ltd.'s (KOSDAQ:239610) Shares After Tumbling 25%HLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders that were waiting for something to happen have been dealt a blow...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023)Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 08HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$44.7m).
分析記事 • Nov 13HLscience Co., Ltd.'s (KOSDAQ:239610) 30% Share Price Plunge Could Signal Some RiskHLscience Co., Ltd. ( KOSDAQ:239610 ) shares have retraced a considerable 30% in the last month, reversing a fair...
分析記事 • Sep 24There's Reason For Concern Over HLscience Co., Ltd.'s (KOSDAQ:239610) Massive 26% Price JumpHLscience Co., Ltd. ( KOSDAQ:239610 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Sep 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 110% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩87.4b market cap, or US$65.8m).
Reported Earnings • Mar 21Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022)Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
New Risk • Jul 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 50% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩103.1b market cap, or US$79.2m).
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021)Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,400, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total loss to shareholders of 51% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Sep 30HLscience Co., Ltd. (KOSDAQ:A239610) announces an Equity Buyback for KRW 3,000 million worth of its shares.HLscience Co., Ltd. (KOSDAQ:A239610) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares according to the contract with Mirae Asset Daewoo Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on October 04, 2023. As of September 29, 2022, the company had 145,575 and 0 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 17x in the Personal Products industry in South Korea. Total loss to shareholders of 65% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Is New 90 Day High Low • Feb 26New 90-day low: ₩40,900The company is down 3.0% from its price of ₩42,238 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period.
お知らせ • Feb 06HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Dec 28New 90-day high: ₩47,700The company is up 1.0% from its price of ₩47,050 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
Upcoming Dividend • Dec 22First Dividend Is ₩400 Per ShareWill be paid on the 21st of April to those who are registered shareholders by the 29th of December. This is the first dividend for HLscience since going public. The average dividend yield among industry peers is 0.6%.
Is New 90 Day High Low • Oct 16New 90-day low: ₩44,000The company is down 22% from its price of ₩56,300 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩44,550The company is down 18% from its price of ₩54,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.